Notice Number: NOT-CA-14-033

Key Dates
Release Date: March 24, 2014
Estimated Publication Date of Announcement: Summer 2014
First Estimated Application Due Date: Fall 2014
Earliest Estimated Award Date: Summer 2015
Earliest Estimated Start Date: Summer 2015

Issued by
National Cancer Institute (NCI)

Purpose

The National Cancer Institute (NCI) supports the development of translational nanotechnologies with applications in the diagnosis and therapy of cancer through its Alliance for Nanotechnology in Cancer program. Cancer nanotechnology is widely viewed as a promising and highly innovative field, with the potential for transformative scientific advancements and practical applications relevant to cancer.

The Funding Opportunity Announcement (FOA) announced by this Notice, to be issued by the NCI, will solicit cooperative agreement applications to establish a network of Centers of Cancer Nanotechnology Excellence (CCNEs). This initiative is open to all qualified applicants regardless of whether or not they participated in the previous cycle of the program.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive applications.  

This FOA will utilize the U54 activity code. Details of the planned FOA are provided below.

Research Initiative Details

The FOA announced by this Notice will be open to all qualified applicants with the appropriate expertise to establish, evolve, and maintain a cancer nanotechnology research program. The program is designed to link physical scientists, engineers, and technologists working at the nanoscale with cancer biologists and oncologists to develop new cancer interventions based on nanotechnology.

This Notice announces the intent to publish a FOA for U54 Centers of Cancer Nanotechnology Excellence (CCNEs). It is expected that as a result of this upcoming RFA, 5-6 CCNEs will be established, supported by set aside funds of $12-13 million/year. The RFA is expected to be published mid-summer 2014. CCNEs will be expected to develop research and translational capabilities to advance new cancer interventions based on nanotechnology. Each center will consist of several projects working towards a common goal with a balance between discovery research and translation efforts.

Further details will be included in the forthcoming FOA.

Applications are not being solicited at this time.

Inquiries

Please direct all inquiries to:

Dr. Piotr Grodzinski
National Cancer Institute (NCI)
Telephone: 301-451-8983
Email: [email protected]